The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma
Authors:
- 9 May 2011
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 87 (2) , 123-129
Abstract
Natural killer (NK)/T‐cell lymphoma cases are rarely discovered using positron emission tomography/computed tomography (PET/CT). We compared the utility of PET/CT and that of conventional methods (CMs; CT with IV contrast, biopsies from primary sites, and bone marrow examinations) in the staging of extranodal NK/T‐cell lymphoma. Nineteen untreated patients with extranodal NK/T‐cell lymphoma at three institutions were analyzed. PET/CT and CMs were applied for initial workups following diagnosis. PET/CT and CMs were compared and evaluated for their ability to detect tumor lesions and their influence on the staging and treatment strategies. In total, 116 lesions were detected by CM and PET/CT. Using PET/CT, 108 lesions (93%) were discovered. The number of nodal lesions was 28: all were positive by PET/CT and 26 (93%) by CMs. The number of extranodal lesions was 89: 84 (94%) and 54 (61%) lesions were positive by PET/CT and CMs, respectively. PET/CT was superior to CMs in detecting cutaneous lesions [31/31 lesions (100%) vs. 20/31 lesions (65%), respectively; P = 0.042]. Bone marrow involvement was confirmed pathologically in only seven patients; four cases (57%) were positive by PET/CT. Using CMs, ten patients (53%) were stages I–II and nine (47%) were stages III–IV. Using PET/CT, eight patients (42%) were in stages I–II and 11 (58%) were in stages III–IV. PET/CT findings altered the stage and treatment strategy in two cases (11%). Our study demonstrated that PET/CT is a useful tool for detecting extranodal lesions in NK/T‐cell lymphoma, particularly cutaneous lesions. PET/CT may therefore influence future staging and treatment strategies.Keywords
This publication has 26 references indexed in Scilit:
- 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 PatientsJournal of Nuclear Medicine, 2009
- The Value of [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Extranodal Natural Killer/T—Cell LymphomaClinical Lymphoma Myeloma and Leukemia, 2008
- Progress in understanding and managing natural killer‐cell malignanciesBritish Journal of Haematology, 2007
- FDG-PET in T-cell and NK-cell neoplasmsAnnals of Oncology, 2007
- The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphomaCancer, 2007
- Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission TomographyMolecular Imaging and Biology, 2006
- Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Leukemia and Lymphoma of Natural Killer CellsJournal of Clinical and Experimental Hematopathology, 2005
- Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphomaBritish Journal of Cancer, 2004
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003